<DOC>
	<DOCNO>NCT01407679</DOCNO>
	<brief_summary>To evaluate therapeutic effect oral alitretinoin ( Toctino® ) treatment CLE respect proportion responder base Revised Cutaneous Lupus Disease Area Severity Index ( RCLASI ) activity score skin lesion baseline 24 week treatment late assessment patient withdraw prematurely . Response define reduction 50 % total RCLASI compare baseline value ( `` RCLASI 50 '' ) .</brief_summary>
	<brief_title>Efficacy Safety Oral Alitretinoin ( Toctino® ) Treatment Patients With Cutaneous Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>A clinical histological diagnosis CLE ( DLE , SCLE , LET ) fail respond topical corticosteroid ; Total RCLASI activity score skin lesion &gt; 6 ( least 3 point least 2 location ) ; At least one primary preferably 2 method contraception ; Systemic Lupus Erythematosus ( SLE ) major systemic organ involvement , e.g . clinical significant renal involvement , require systemic medical treatment disease ; Clinically significant illness may influence outcome study four week study ; Active severe infection disease , include chronic localize ; Patients hepatic insufficiency ( AST , ALT &gt; 2.5 x ULN ) , severe renal failure ( creatinine clearance &lt; 60ml/min ) , hypercholesterolemia characterize : 1 . Fasting triglyceridemia &gt; 1.5 x upper limit normal ( ULN ) 2 . Fasting total cholesterol &gt; 1.5 x ULN 3 . Fasting lowdensity lipoprotein ( LDL ) cholesterol &gt; 1.5x ULN Patients know hypersensitivity retinoids vitamin A derivative , study medication component , especially soybean oil partly hydrogenate soybean oil ; Patients cardiovascular risk factor would exclude start dose 30 mg alitretinoin ; Topical corticosteroid within 14 day prior dose ; Patients treat systemic topical retinoids within 4 week start study treatment ; Drugs potential drugdrug interaction , systemic tetracycline , ketoconazole , St. John‟s Wort within 1 week , receive systemic itraconazole within 2 week , start study treatment ; Initiation change dose current systemic medication treatment CLE/SLE prior study ( time depend drug class halflife ) ; Treatment immunosuppressive drug reason , 4 week prior within study ; Concomitant medication drug know photosensitize potential , e.g . tetracycline , griseofulvin , thiazide , furosemide , sulfonamide tolbutamide ; Drugs associate CLEinduction : terbinafine , hydrochlorothiazide , diltiazem , verapamil , nifedipine , nitrendipine , fluorouracil , penicillamine , infliximab , adalimumab , etanercept , pantoprazole ; Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cutaneous lupus erythematosus</keyword>
	<keyword>discoid lupus erythematosus</keyword>
	<keyword>subacute cutaneous lupus erythematosus</keyword>
	<keyword>lupus erythematosus tumidus</keyword>
</DOC>